Baudax Bio Inc. (NASDAQ:BXRX) has seen 34.72 million shares traded in the recent trading session. The company, currently valued at $1.48M, closed the recent trade at $4.84 per share which meant it gained $1.69 on the day or 53.49% during that session. The BXRX stock price is -6231.82% off its 52-week high price of $306.46 and 67.98% above the 52-week low of $1.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.24 million shares traded. The 3-month trading volume is 1.28 million shares.
The consensus among analysts is that Baudax Bio Inc. (BXRX) is a Hold stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 1 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.53.
Baudax Bio Inc. (NASDAQ:BXRX) trade information
Sporting 53.49% in the green today, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the BXRX stock price touched $4.84 or saw a rise of 29.75%. Year-to-date, Baudax Bio Inc. shares have moved -0.94%, while the 5-day performance has seen it change -7.35%. Over the past 30 days, the shares of Baudax Bio Inc. (NASDAQ:BXRX) have changed 56.72%. Short interest in the company has seen 0.36 million shares shorted with days to cover at 0.26.
Wall Street analysts have a consensus price target for the stock at $24.00, which means that the shares’ value could jump 79.83% from the levels at last check today. The projected low price target is $24.00 while the price target rests at a high of $24.00. In that case, then, we find that the latest price level in today’s session is -395.87% off the targeted high while a plunge would see the stock gain -395.87% from the levels at last check today.
Baudax Bio Inc. (BXRX) estimates and forecasts
The company’s shares have lost -89.21% over the past 6 months, compared to 11.30% for the industry. Revenue growth from the last financial year stood is estimated to be 200.90%.
1 analysts offering their estimates for the company have set an average revenue estimate of $960k for the current quarter. 1 have an estimated revenue figure of $1.56 million for the next quarter concluding in Dec 2022. Year-ago sales stood $281k and $400k respectively for this quarter and the next, and analysts expect sales will grow by 241.60% for the current quarter and 290.00% for the next.
Baudax Bio Inc. is expected to release its next earnings report between March 14 and March 20 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Baudax Bio Inc. (NASDAQ:BXRX)’s Major holders
Insiders own 0.32% of the company shares, while shares held by institutions stand at 6.61% with a share float percentage of 6.63%. Investors are also buoyed by the number of investors in a company, with Baudax Bio Inc. having a total of 27 institutions that hold shares in the company. The top two institutional holders are Alyeska Investment Group, L.p. with over 0.92 million shares worth more than $0.78 million. As of Jun 29, 2022, Alyeska Investment Group, L.p. held 4.60% of shares outstanding.
The other major institutional holder is Renaissance Technologies, LLC, with the holding of over 0.64 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $0.54 million and represent 3.20% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 0.58% shares in the company for having 0.12 million shares of worth $98560.0 while later fund manager owns 74208.0 shares of worth $62705.0 as of Jun 29, 2022, which makes it owner of about 0.37% of company’s outstanding stock.